Stock Events

Harmony Biosciences 

$34.97
46
+$0.13+0.37% Thursday 20:00

Statistics

Day High
35.37
Day Low
34.63
52W High
40.6
52W Low
18.79
Volume
393,923
Avg. Volume
427,065
Mkt Cap
2.04B
P/E Ratio
18.45
Dividend Yield
-
Dividend
-

Upcoming

29
OCT
Earnings
 

Earnings

29OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0
0.32
0.65
0.97
Expected EPS
0.663333
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HRMY. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap7.16B
Jazz Pharmaceuticals competes in the narcolepsy market, directly challenging Harmony Biosciences' key product, Wakix.
Avadel Pharmaceuticals
AVDL
Mkt Cap1.46B
Avadel Pharmaceuticals is developing treatments for narcolepsy, positioning it as a competitor in Harmony Biosciences' core market.
Axsome Therapeutics
AXSM
Mkt Cap4.27B
Axsome Therapeutics has a pipeline addressing central nervous system disorders, including narcolepsy, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap21.38B
Teva Pharmaceutical Industries offers products for sleep disorders, including narcolepsy, competing with Harmony Biosciences.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on neurological disorders and has a broad portfolio that could compete with Harmony Biosciences' treatments.
Sage Therapeutics
SAGE
Mkt Cap514.65M
Sage Therapeutics is developing therapies for central nervous system disorders, potentially competing with Harmony Biosciences.
Supernus Pharmaceuticals
SUPN
Mkt Cap1.94B
Supernus Pharmaceuticals has a focus on central nervous system diseases, including treatments for sleep disorders.
Palatin Technologies
PTN
Mkt Cap31.57M
Palatin Technologies is involved in developing treatments for various conditions, including those affecting the central nervous system, potentially competing with Harmony.

Analyst Ratings

49.6$Average Price Target
The highest estimate is $56.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Show more...
CEO
Employees
246
Country
US
ISIN
US4131971040

Listings

XNAS
US
HRMY